Following reports in Israeli press last week that struggling generics giant Teva Pharmaceutical Industries (NYSE: TEVA) is gearing up to slash its global workforce, the company announced today a radical shakeup of its executive team which included, as expected, the ousting of R&D chief Michael Hayden.
Rejecting boldly those who had lobbied for a breakup of the company’s generics and branded divisions, Teva will also unify its global groups for generics and specialty medicines, including R&D functions.
Rob Koremans, president and chief executive of the specialty medicines unit and Dipankar Bhattacharjee, president and CEO of the global generics unit, will leave at the end of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze